Loading clinical trials...
Loading clinical trials...
A Phase III Randomized Controlled Clinical Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Conditions
Interventions
BL-M07D1
Liposomal Doxorubicin
+2 more
Locations
1
China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Start Date
April 1, 2026
Primary Completion Date
December 1, 2028
Completion Date
December 1, 2028
Last Updated
April 22, 2026
NCT06915025
NCT06710548
NCT02637934
NCT05080946
NCT04657068
NCT05281471
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions